Possible treatments for sporadic Creutzfeldt-Jakob disease: a systematic review
DOI:
https://doi.org/10.11606/issn.1679-9836.v102iespe-203760Keywords:
Prion disease, Sporadic Creutzfeldt-Jakob disease, TreatmentAbstract
Prion Diseases are rare and fatal diseases that compromises the Nervous System, in which occurs an abnormal accumulation of a protein known as Prion Scrapie (PrPsc). PrPsc is a mutation of a brain tissue protein called Normal Cellular Prion (PrPc) and the accumulation of PrPsc causes spongiform deficiencies. Creutzfeldt-Jakob Disease (CJD) is one of the various Prion Diseases and its sporadic form (sCJD) is the most prevalent. Considering the relentless and rapid progression of the disease, the invariably lethal outcome and the scarcity of therapeutic options for Prion Diseases, especially sCJD, effective treatments become necessary. Thus, the objective of this systematic review is to analyze and identify therapeutic options aimed at sCJD. This research was carried out in the Pubmed and Cochrane databases with the Mesh Terms “Sporadic Creutzfeldt-Jakob disease” and “Treatment”, and the boolean “AND”. Four articles in English were selected, that most aligned ones with the work targets. As the outcome of this research, came to a conclusion that two drugs were well tolerated by the patients, nevertheless they did not deliver a better life quality neither achieved an extended life span. Other drugs are being tested in adult patients, some in clinical trials exhibited good efficacy, minimizing cognitive deficits in CJD patients. However, the studies require a greater number of trials in a wide amount of patients for better conclusion that addresses the treatment of this severe and fatal disease.
Downloads
References
Berti V. Príon e doenças priônicas: uma revisão. Colloquium Vitae. 2020;12(2):47-58. doi: https://doi.org/10.5747/cv.2020.v12.n2.v296
Prusiner SB. Príons. PNAS. 1998; 95(23):13363-13383. doi: https://doi.org/10.1073/pnas.95.23.13363
Costa AL, Silva-Junior AC. Prions: uma revisão de suas propriedades bioquímicas e das características patológicas das encefalopatias espongiformes transmissíveis. Rev Arq Cient (IMMES). 2018;1(1):04-13. doi: https://doi.org/10.5935/2595-4407/rac.immes.v1n1p4-13
Machado R, Miranda A, Dantas B. Análise bibliográfica: proteína príon e encefalopatias transmissíveis. Rev Ciên Saúde Nova Esperança. 2020;18(2):88-7. doi: https://doi.org/10.17695/revcsnevol18n2p88-97
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Med. 2009;6(7):e1000100. doi: https://doi.org/10.1371/journal.pmed.1000100
Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128(1):305-310. doi: https://doi.org/10.1097/PRS.0b013e318219c171
Collinge J, Gorham M, Hudson F, Kennedy A, Keogh G, Pal S, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol. 2009;8(4):334-44. doi: https://doi.org/10.1016/S1474-4422(09)70049-3
Geschwind MD, Kuo AL, Wong KS, Haman A, Devereux G, Raudabaugh BJ, et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology. 2013;81(23):2015-23. doi: https://doi.org/10.1212/WNL.0b13e3182a9f3b4
Haïk S, Marcon G, Mallet A, Tettamanti M, Welaratne A, Giaccone G, et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(2):150-8. doi: https://doi.org/10.1016/S1474-4422(13)70307-7
Varges D, Manthey H, Heinemann U, Ponto C, Schmitz M, Schulz-Schaeffer WJ, et al. Doxycycline in early CJD: a double-blinded randomised phase II and observational study. J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):119-125. doi: http://dx.doi.org/10.1136/jnnp-2016-313541
Mahat S, Asuncion RMD. Kuru. [Updated 2022 Jun 5]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559103/
Duncan BB, Schmidt MI, Giugliani ERJ. Medicina ambulatorial: condutas de atenção primária baseada em evidências. 3a ed. Porto Alegre: Artmed Editora; 2004.
Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wiltfang J, et al. Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology. 2004;62(5):714-8. doi: https://doi.org/10.1212/01.WNL.0000113764.35026.EF
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Aline Gabriele Etur dos Santos, Gabriel Barbosa Huszcz, Henrique Garutti dos Santos, Dyana Alves Henriques
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
